Wang Jiahao, Du Qingdi, Sun Xueyan, Tao Rong, Zhang Zuojuan, Li Wei, Liu Wenjing, Wei Li, Tian Zongsheng, Xu Xueliang
Department of Respiratory and Critical Care Medicine, Linyi People's Hospital, Linyi, China.
Department of Diagnostics and Clinical Medicine, Shandong Medical College, Linyi, China.
Front Oncol. 2025 Jul 25;15:1645580. doi: 10.3389/fonc.2025.1645580. eCollection 2025.
Targeted therapies for anaplastic lymphoma kinase () mutations in non-small cell lung cancer (NSCLC) generally extend survival and alleviate symptoms. However, significant tumor reduction or complete remission remains rare. We report a rare case of a 14-year-old girl, whose father and grandfather both had lung cancer, diagnosed with advanced, multi-site metastatic -positive NSCLC. She was treated with Iruplinalkib, a newly approved targeted therapy in China, resulting in remarkable tumor shrinkage. The patient presented with severe symptoms, including persistent cough, pain, and hemoptysis. A lung CT scan revealed a large mass, which was pathologically diagnosed as pulmonary adenocarcinoma. After initiating Iruplinalkib therapy, the primary tumor rapidly decreased in size by 80.3%, from 132 mm × 97 mm to 26 mm × 21 mm, within one month. Most metastatic lesions also showed significant regression. By six months, the pulmonary tumor had almost disappeared. This case underscores the potential of Iruplinalkib, which is currently not available outside of China, to induce rapid and profound tumor regression in -positive NSCLC, particularly in adolescent patients with aggressive clinical presentations. We hope that the anticancer efficacy of Iruplinalkib will be recognized globally and that it will become accessible to -positive lung cancer patients worldwide.
针对非小细胞肺癌（NSCLC）中间变性淋巴瘤激酶（ALK）突变的靶向治疗通常可延长生存期并缓解症状。然而，显著的肿瘤缩小或完全缓解仍然很少见。我们报告了一例罕见病例，一名14岁女孩，其父亲和祖父均患有肺癌，被诊断为晚期、多部位转移的ALK阳性NSCLC。她接受了中国新批准的靶向治疗药物艾乐替尼治疗，肿瘤显著缩小。患者出现严重症状，包括持续咳嗽、疼痛和咯血。肺部CT扫描显示一个大肿块，经病理诊断为肺腺癌。开始使用艾乐替尼治疗后，原发肿瘤在一个月内迅速缩小，大小从132 mm×97 mm降至26 mm×21 mm，缩小了80.3%。大多数转移灶也显示出明显消退。到六个月时，肺部肿瘤几乎消失。该病例强调了目前在中国境外无法获得的艾乐替尼在ALK阳性NSCLC中诱导快速且显著的肿瘤消退的潜力，特别是在具有侵袭性临床表现的青少年患者中。我们希望艾乐替尼的抗癌疗效能在全球得到认可，并使全球ALK阳性肺癌患者能够使用。
